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Abstract
Background: Most of the steps involved in the initiation and progression of Hürthle (oncocytic,
oxyphilic) cell carcinomas of the thyroid remain unknown.
Methods:  Using differential display and semiquantitative RT-PCR we found, among other
alterations, overexpression of the gene encoding the Core I subunit of the complex III of the
mitochondrial respiratory chain in a follicular carcinoma composed of Hürthle cells.
Results: Similar high levels of Core I gene expression were detected in nine follicular carcinomas
(seven with Hürthle cell features), in seven microfollicular adenomas (one with Hürthle cell
features) and in one micro/macrofollicular adenoma, in contrast to a lower/normal expression in
nine papillary carcinomas (three with Hürthle cell features) and five macrofollicular adenomas (one
of which displaying Hürthle cell features). No significative correlation was found between Core I
overexpression and the proliferative activity of the lesions.
Conclusions: We conclude that Core I overexpression in thyroid tumours is not associated with
malignancy, Hürthle cells or proliferative activity. The pathogenetic mechanism linking Core I
overexpression to the microfollicular pattern of growth of thyroid tumours remains to be clarified.
Background
Neoplastic progression is a prolonged and stepwise proc-
ess involving a series of molecular alterations that culmi-
nate in invasion and metastasis. Such molecular
alterations usually result in the modification of gene
expression in cancer cells.
Some consistent molecular changes have been previously
described in functioning thyroid adenomas – TShR and Gs
alpha gene mutations – [1] as well as in papillary thyroid
carcinomas: RET/PTC and trk rearrangement [2,3] and B-
RAF mutation [4]. For follicular adenomas and follicular
carcinomas the picture is less clear if one excludes the
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relatively frequent occurrence of ras activation/mutation
[5,6] and PAX8-PPARgamma1 fusion [7].
Carcinomas with Hürthle (oncocytic, oxyphilic) cell fea-
tures typically harbour the genetic alterations associated
to the predominant histotype of the lesion – e.g. the high
prevalence of RET/PTC rearrangements and B-RAF muta-
tions in the Hürthle cell variant of papillary thyroid carci-
nomas [4,8].
Haugen et. al. [9], using the differential display method,
reported an increased expression of mitochondrial mRNA
and mitochondrial proteins in a series of papillary thyroid
carcinomas and advanced that such overexpression
appeared to be associated with the increased number and/
or size of mitochondria, observed in most of the tumours.
In an attempt to identify genes putatively involved in the
origin and/or development of follicular thyroid carcino-
mas composed of Hürthle cells we applied Liang's
method of differential display [10] to one of such
tumours and to the corresponding adjacent "normal"
parenchyma. After having identified one of the genes
overexpressed in the carcinoma as the Core I subunit of
the complex ubiquinol-cytochrome c-reductase (complex
III) of the mitochondrial respiratory chain (MRC), we
compared its level of expression in the follicular Hürthle
cell carcinoma with those observed in 30 additional cases
of benign and malignant thyroid tumours with different
histotypes, and with or without Hürthle cell features.
Methods
Materials
The study was performed in two steps. First it dealt with a
case of follicular carcinoma composed of Hürthle cells. It
was afterwards expanded in order to include, for compar-
ative purposes, 30 thyroid tumours with or without
Hürthle cell features. The 30 tumours were classified
according to Rosai et al. [11] and Hedinger et al. [12] as
follicular adenoma (n = 13; 7 microfollicular adenomas,
5 macrofollicular adenomas and one micro/macrofollicu-
lar adenoma), follicular carcinoma (n = 8) and papillary
carcinoma (n = 9). One of the microfollicular adenomas,
one of the macrofollicular adenomas, six of the follicular
carcinomas and three of the papillary carcinomas were
composed of Hürthle cells. Frozen sections from each case
were used to separate samples from the tumours and the
respective adjacent normal parenchyma; samples were
immediately collected, after surgical resection in the Uni-
versity Hospital of S. João, Porto, Portugal, quick frozen in
liquid nitrogen and stored at -70°C.
Immunohistochemistry
Paraffin-embedded specimens were used in the immuno-
histochemical study. Serial sections were immunostained
with monoclonal antibody for a human nuclear prolifer-
ation-associated antigen (MIB-1, Immunotech). Immu-
nostaining was performed using the avidin-biotin-
peroxidase (ABC) complex as described by Holm et al.
[13], with an additional step for microwave antigen
retrieval (5 × 1.5 min at 750 W). Previously tested positive
controls were included in the series. As negative controls,
immunoglobulins of the same subclass and in the same
protein concentrations as the primary specific antibody
were used. Evaluation of the percentage of immunoreac-
tive cells for MIB-1 was made by counting 1000 tumour
cells in random fields.
Differential display (DD)
Total RNA from 50–100 mg of frozen powdered lesions
was isolated either using the acid guanidinium thiocy-
anate-phenol-chloroform extraction method as described
by Chomczynski and Sacchi [14], or with Tripure™ Isola-
tion Reagent (Roche Diagnostics Corporation, Indianapo-
lis, IN, USA). In order to remove genomic DNA, samples
were treated with LiCl. An amount of 0.2 µg of total RNA
obtained from the follicular carcinoma and the corre-
spondent adjacent normal tissue were reverse transcribed
in a 20 µl reaction volume using either T13A, T13G, or T13C
(Table 1) and subsequently amplified by PCR using four
different arbitrary primers: D390, D433, D492, D495 (Table 1)
essentially as described [10]. The cycling parameters were
the following: 94°C for 5 min; 40 cycles with 94°C for 30
s, 40°C for 1 min and 72°C for 2 min; followed by 72°C
for 10 min. Duplicates were made for each primer combi-
nation and PCR was performed twice to confirm the
results and eliminate false positives. To assure that the
band patterns obtained in DD could not be originated
from contaminating DNA, PCR was performed for all the
primer combinations directly on the RNA from normal
and tumour cells. In addition, PCR negatives controls
were performed by replacing cDNA with water. PCR prod-
ucts were analyzed on a 6% sequencing gel. The cDNA
bands of interest (unique to tumour or normal thyroid)
were cut out of the gel, eluted and reamplified by PCR.
Semiquantitative RT-PCR
For each sample 1.0 µg of RNA was reverse transcribed in
a reaction volume of 20 µl in the presence of 4 mM dNTP,
1.0 U µl-1 RNase Inhibitor, 2.5 µM random primer P
(dN)6 and 10 U µl-1 M-MLV reverse transcriptase. Reverse-
transcribed cDNAs (0.25 µg) from normal and neoplastic
tissues were co-amplified with a set of primers for the
housekeeping gene β-actin (primers Actin-R and Actin-F)
(Table 1) and a set of primers for the differentially
expressed gene – Core I gene- (primers Core I-R and Core
I-F) (Table 1). All the quantitations were done in tripli-
cate. The PCR products were separated in an agarose gel
(2%), and stained with ethidium bromide. The intensity
of the fluorescence was automatically measured andBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/12
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integrated using the genescan software "Image Master"
(Pharmacia).
The optimal number of cycles of amplification to allow
quantitation of Core I and β-actin genes PCR products was
determined using a sample of normal thyroid and the
same primers used for the semiquantitative PCR. Samples
were subjected to a number of amplification cycles rang-
ing from 10 to 30 cycles. PCR products were separated in
a 2% agarose gel and stained with ethidium bromide. The
intensity of the fluorescence was automatically measured
and integrated using the genescan software "Image Mas-
ter" (Pharmacia). A close to exponential increase in the
amount of PCR product was obtained between 21 and 26
cycles for both Core I and β-actin products (Figure 1). In
all of our RT-PCR experiments 24 cycles were used.
Sequence analysis
Sequencing of the cDNA fragments was performed using
ABI PRISM™ DyeTerminator Cycle Sequencing Kit accord-
ing to the protocol supplied by the manufacturer (Perkin
Elmer). Sequencing reaction parameters were the follow-
ing: 15 s at 94°C, 20 s at 45°C and 4 min at 60°C for 30
cycles. After purification and denaturation the sequencing
products were loaded onto a 6% sequencing gel and
runned for 7 h at 30 W constant power on an ABI PRISM™
DNA sequencer.
Comparison of the cDNA sequences with known sequences 
from GenBank database
The nucleotide sequences obtained were compared with
known sequences by searching the GenBank database
with BLASTN and BLASTX [15,16] programs. In order to
confirm that the sequences determined for the isolated
bands could actually be produced by the specific arbitrary
primer, we performed an alignment between the afore-
mentioned primer and the sequence of the putative gene.
This alignment was accomplished using GeneJokey soft-
ware for Macintosh (Taylor P L (1990) GeneJokey –
Sequence Processor, Biosoft, Cambridge) allowing up to
three mismatches.
Southern blot
For Southern blot analysis, 10 µg of DNA from normal
blood donors was digested with 1.0 U µl-1 of SmaI enzyme
(Stratagene), separated by agarose gel (0.8%) electro-
phoresis and transferred onto nylon filters (Hybond N+,
Amersham). After blotting, the nylon membranes were
prehybridized in a 0.5 M sodium phosphate buffer, 1 mM
EDTA pH = 8 and 7% SDS. cDNA fragments were labelled
by random priming according the protocol supplied by
manufacturer (Amersham) using [α-32P] dCTP (~3000 Ci/
mmol). The probe was purified, denatured and added to
the prehybridisation solution; the hybridisation was per-
formed overnight at 65°C. Nylon membranes were
exposed to a x-ray film (Amersham-MP hyperfilms) at -
70°C. Band T1 (see Results) was reamplified, purified
from 2% agarose gel and used as a probe. From the restric-
tion map of Core I protein, band T1 was expected to
hybridize with a 2.5 Kb fragment of human genomic DNA
digested with SmaI.
Construction and screening of a human thyroid cDNA 
library
The cDNA library was constructed using a λ ZAP express®
cDNA cloning Kit and a gigapack® III Gold Kit (Strata-
gene®, La Jolla, CA) according to the manufacturer's
instructions. Briefly, poly(A)+ RNA was purified from total
RNA isolated from normal human thyroid tissue by affin-
ity chromatography using an oligo poly(dT) cellulose
Table 1: Primer sequences for DD and RT-PCR analysis.
Name Length Sequence (5' to 3')
DD
T13A 14-mer TTTTTTTTTTTTTA
T13G 14-mer TTTTTTTTTTTTTG
T13C 14-mer TTTTTTTTTTTTTC
D390 10-mer GTTGCGATCC
D433 10-mer CTTGATTGCG
D492 10-mer CAGTGTAGTC
D495 10-mer TCGATACAGG
RT-PCR
Core I R 19-mer GCAGAACTGTAGTCTGGAA
Core I F 19-mer GGAGTAGTGCCATCTAGAT
Actin R 20-mer ATGCTATCACCTCCCCTGTG
Actin F 21-mer AAATCGTGCGTGACATTAAGGBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/12
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Quantification of Core-1 and β-actin mRNA by RT-PCR analysis Figure 1
Quantification of Core-1 and β-actin mRNA by RT-PCR analysis. A. Determination of the optimal number of amplification 
cycles for quantification of Core-1 and β-actin mRNA. B. Semiquantitative RT-PCR analysis of Core-1 mRNA expression. For 
each sample, constant amounts of reverse-transcribed RNA were amplified together with β-actin housekeeping gene. N, tripli-
cates of samples of normal thyroid tissue; T, triplicates of samples of follicular carcinoma. * Values are expressed in arbitrary 
units.
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column (Poly (A) Quick® mRNA isolation Kit – Strata-
gene®, La Jolla, CA), and then used as a template for cDNA
synthesis. Double-stranded cDNA inserts (>0.5 kb) were
ligated to EcoRI and XhoI cloning sites in λ ZAP express
phage vector. The titer of the amplified library was 8.45 ×
109  pfu/ml, corresponding to 97.5% of recombinant
phages. The corresponding to 1 × 106 pfu of human thy-
roid cDNA library was screening using the cloned cDNA
fragments isolated by differential display as described by
the commercial supplier (Stratagene®, La Jolla, CA).
Inserts from the positive clones were sequenced by auto-
mated sequence analysis.
Statistical analysis
The analyses of the results of Core I gene expression were
performed using the student t-test (Unpaired). For MIB-1
the correlation studies were performed using a simple
regression test. A p value < 0.05 was considered statisti-
cally significant.
Results
DD
The DD analysis of mRNA revealed seven bands differen-
tially expressed in normal thyroid tissue and in the follic-
ular Hürthle cell carcinoma. Four bands (N1-N4) were
present in normal tissue samples and displayed either a
very weak signal or no detectable signal in the tumour
samples; the remaining three bands (T1-T3) were present
in the tumour samples and absent in the normal tissue
samples (data not shown).
Limitations in the amount of tissue necessary for the
molecular studies and, consequently, limitations in the
available amount of RNA – unfortunately a common sit-
uation whenever surgical specimens are used – hindered
us from performing confirmation of DD by Northern
blot. To confirm the specificity and reproducibility of dif-
ferentially expressed bands, DD analyses were repeated
and duplicates of normal and tumour tissues were per-
formed for all primer combinations. Furthermore, PCR
negatives were run in a sequencing gel and after exposi-
tion to an autoradiographic film no signal was detected
(data not shown). PCR was also performed without previ-
ous RT reaction; in these conditions no bands were origi-
nated (data not shown). These results ensure that there
was no DNA contamination in the samples collected from
the follicular Hürthle cell carcinoma and adjacent normal
thyroid tissue.
Reamplification by PCR
Only six bands out of the seven differentially expressed
bands were successfully reamplified by PCR (N1, N2, N3,
T1, T2, T3). The approximate lengths of the bands were
determined, in a 2% agarose gel, as being about 200 bp,
200 bp, 200 bp, 300 bp, 250 bp, and 250 bp respectively.
Sequencing
Direct sequencing was possible only in band T1, in which
there were 289 bases. cDNA fragments N1, N2, N3, T2
and T3 were cloned into the pCR® 2.1 vector using the TA
Cloning System Kit (Invitrogen®) according to the manu-
facturer's instructions and sequenced using the M13 vec-
tor primers giving reading sequences of 192 bp, 170 bp,
172 bp, 239 bp and 242 bp respectively.
Homology search
Regarding bands N2 and N3, the homology search did not
lead to the identification of any previously known gene
(data not shown). The 192 bp cDNA fragment from band
N1 had 100% homology to Homo sapiens thyroglobulin
gene (Accession nr: AF305872). The 289 bp cDNA frag-
ment from band T1 had 98% homology to human Core I
protein (Accession nr: AW075678). The 239 bp cDNA
fragment from band T2 had 100% homology to rRNA 28s
(Accession nr: M11167) and the 242 bp cDNA fragment
from band T3 had 100% homology to Homo sapiens
mRNA for KIAA1468 protein (Accession nr: AB040901).
Southern blot confirmation
To confirm that the sequence of band T1 corresponds to
the human Core I gene, band T1 was used as a probe in
Southern blot analysis. Hybridization with a fragment of
SmaI digested human genomic DNA of the expected size
(2.5 Kb) (see Methods) confirmed the results obtained by
the homology search. Our conclusion is also supported by
the presence of the arbitrary primer sequence in the
sequence of Core I protein mRNA near the 5' end of the
gene. The predicted annealing position determines the
synthesis of a cDNA fragment with 274 bp, approximately
the length of band T1.
Screening of the human thyroid cDNA library
The cDNA library was screened using the cDNA fragments
isolated by DD, that did not show any homology with
known genes. The screening process using band N2 as a
radiolabelled probe led to the isolation of positive clones.
The insert of one of the clones was sequenced and the
search for homology using the GenBank database showed
that the clone had 97% homology to human ribosomal
protein L3 (Accession nr: X73460). The screening process
using band N3 as a radiolabelled probe lead to the isola-
tion of positive clones. The insert of one of the clones was
sequenced and the search for homology using the Gen-
Bank database showed that the clone had 97% homology
to Homo sapiens hypothetical gene (LOC125510), mRNA
(Accession nr: XM_074963).
Follicular Hürthle cell carcinoma vs normal thyroid
The results obtained in the study of the follicular Hürthle
cell carcinoma are summarized in Table 2.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/12
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Table 2: Summary of the data on differentially expressed genes in the follicular Hürthle cell carcinoma.
Genes overexpressed in the tumour:
-T1 (Core I protein)
-T2 (rRNA 28s)
-T3 (Homo sapiens mRNA for KIAA1468 protein)
Genes underexpressed in the tumour:
-N1 (Homo sapiens thyroglobulin gene)
-N2 (ribosomal protein L3)
-N3 (Homo sapiens hypothetical gene (LOC125510), mRNA)
-N4 (not determined for technical reasons)
Table 3: RT-PCR. Level of expression of Core I in tumours and corresponding normal tissues.
Case Age/Sex Diagnosis Tumour Core I/
Actin %a
Normal Core I/
Actin %a
Level of Expression 
*
MIB-1b %
1 64/F HFC 46.2 ± 0.3 21.0 ± 0.5 2.2 1.1
2 33/M HFC 52.1 ± 1.8 22.8 ± 1.3 2.3 1.0
3 47/M HFC 52.1 ± 2.2 24.8 ± 1.1 2.1 0.9
4 59/F HFC 54.6 ± 0.8 22.2 ± 1.0 2.5 0.5
5 55/F HFC 47.7 ± 1.2 22.7 ± 0.8 2.1 0.9
6 24/F HFC 50.2 ± 0.9 23.9 ± 1.2 2.1 0.9
7 55/F HFC 41.5 ± 1.2 21.9 ± 1.4 1.9 0.8
8 64/F FC 46.4 ± 2.8 25.8 ± 1.6 1.8 1.1
9 46/F FC 48.9 ± 2.1 23.4 ± 0.8 2.1 1.6
10 71/F HmFA 47.2 ± 2.7 22.6 ± 1.8 2.1 1.1
11 24/F mFA 47.3 ± 3.3 26.4 ± 0.8 1.8 0.3
12 69/F mFA 45.1 ± 2.3 27.6 ± 1.3 1.6 0.0
13 57/F mFA 42.8 ± 1.8 22.5 ± 0.9 1.9 0.5
14 27/F mFA 48.8 ± 2.2 23.2 ± 1.1 2.1 0.9
15 53/F mFA 49.0 ± 2.1 22.7 ± 0.8 2.2 1.1
16 65/F mFA 52.4 ± 2.4 24.9 ± 0.9 2.1 0.7
17 31/F mMFA 35.8 ± 2.3 27.6 ± 1.3 1.3 0.1
18 52/F PC 30.0 ± 0.2 27.3 ± 0.1 1.1 0.7
19 46/F PC 24.2 ± 0.5 26.9 ± 0.1 0.9 1.1
20 52/F PC 39.8 ± 2.6 37.3 ± 0.0 1.1 0.7
21 47/F PC 26.7 ± 3.4 33.5 ± 3.7 0.8 3.0
22 52/F PC 16.7 ± 0.6 24.6 ± 0.4 0.7 0.7
23 68/F PC 24.1 ± 0.8 24.0 ± 0.6 1.0 0.8
24 60/F HPC 20.9 ± 1.2 23.2 ± 0.9 0.9 1.5
25 62/F HPC 16.4 ± 1.2 22.2 ± 0.8 0.7 0.4
26 11/M HPC 27.4 ± 0.9 22.8 ± 2.1 1.2 1.1
27 30/F HMFA 19.9 ± 0.1 28.6 ± 2.3 0.7 0.4
28 42/F MFA 18.5 ± 0.1 24.8 ± 0.1 0.7 0.6
29 52/F MFA 22.7 ± 2.3 25.4 ± 0.3 0.9 1.0
30 62/F MFA 22.3 ± 0.2 23.0 ± 0.1 1.0 0.2
31 54/F MFA 20.9 ± 0.7 25.8 ± 0.8 0.8 0.9
F – Female; M – Male; HFC – Follicular carcinoma composed of Hürthle cells; FC – Follicular carcinoma; PC – Papillary carcinoma; HPC – Papillary 
carcinoma composed of Hürthle cells; mFA – Microfollicular adenoma; MFA – Macrofollicular adenoma; mMFA – Micro/macrofollicular adenoma; 
HmFA – Microfollicular adenoma composed of Hürthle cells; HMFA – Macrofollicular adenoma composed of Hürthle cells; Core I/Actin – Ratio 
between the expression of Core I gene and β-actin gene. *Values are expressed as ratio between the mean values obtained in tumours and normal 
tissues (previous columns). aResults are expressed as mean ± s.d. of three experiments. bOnly tumoural MIB-1 indexes are shown.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/12
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Semiquantitative RT-PCR
Semiquantitative RT-PCR showed that the level of Core I
is 2.2 fold higher in the follicular Hürthle cell carcinoma
than in the adjacent normal thyroid tissue (case 1) (Table
3).
Semiquantitative RT-PCR was also performed in the
remaining 30 cases. The results of this analysis are sum-
marized in Table 3. Sixteen of the cases (eight follicular
carcinomas, seven microfollicular adenomas and a micro/
macrofollicular adenoma) showed overexpression (1.3–
2.5 times higher) of Core I protein in tumour tissue. Four
tumours (two papillary carcinomas and two macrofollic-
ular adenomas) presented lower expression (<0.8 times)
of this gene in tumour tissue than in the normal counter-
part. In seven papillary carcinomas and in three microfol-
licular adenomas the levels of expression were similar
(≥0.8 times and ≤1.2 times) in tumour and normal tissue
(Table 3). The levels of expression in microfollicular and
macrofollicular adenomas, as well as in follicular carcino-
mas and papillary carcinomas were similar regardless of
the presence or absence of Hürthle cell features (Table 3).
Immunohistochemistry
The MIB-1 index of the 31 cases is shown in Table 3. No
significative correlation between MIB-1 index and level of
expression of Core I protein was found (p = 0.927).
Statistical analysis
The statistical analysis of the RT-PCR results revealed sim-
ilar relatively low levels of expression of Core I gene in the
five macrofollicular adenomas (mean ± standard devia-
tion: 0.82 ± 0.13) and in nine papillary carcinomas (0.93
± 0.18), as well high levels of expression in the seven
microfollicular adenomas (1.97 ± 0.21) and nine follicu-
lar carcinomas (2.12 ± 0.21). The expression levels
observed in macrofollicular adenomas and in papillary
carcinomas were significantly lower (p < 0.0001 and p <
0.0001, respectively) than those observed in microfollicu-
lar adenomas and in follicular carcinomas (p < 0.0001
and p < 0.0001, respectively) regardless of the presence or
absence of Hürthle cell features. No significant difference
was found between the expression of Core I gene in malig-
nant tumours and benign tumours (p = 0.824).
Discussion
Using a DD approach we were able to identify six out of
seven differentially expressed cDNA fragments: N1, N2,
N3, T1, T2 and T3 corresponding to Homo sapiens thy-
roglobulin gene, ribosomal protein L3, Homo sapiens
hypothetical gene (LOC125510) mRNA, human Core I
protein, rRNA 28s and Homo sapiens mRNA for KIAA1468
protein, respectively.
The most interesting findings concern the overexpression
(differential expression) of the gene that encodes Core I
protein in the follicular Hürthle cell carcinoma of the thy-
roid. Core I protein is a subunit of the complex III of the
MRC that is located in the inner membrane of the mito-
chondrion and is encoded by a nuclear gene [17]. The
complex III is a transmembrane complex of the inner
mitochondrial membrane encoded by nuclear and mito-
chondrial genes, and its electron-carrier function is essen-
tial for oxidative phosphorylation (OXPHOS) [17].
The detection of a differentially expressed gene encoding
for Core I protein in a follicular carcinoma composed of
Hürthle cells led us to hypothesize that such a finding
might be related to the prominent mitochondrial abnor-
malities that are the hallmark of this type of tumours [18].
In order to explore this possibility we analyzed the expres-
sion of Core I gene in 30 additional benign and malignant
lesions of the thyroid, with or without Hürthle cell fea-
tures. We detected Core I protein overexpression in several
of these lesions, thus ruling out the putative association
between Core I protein overexpression and Hürthle cell
features.
Our data do not fit those recently reported by Haugen et.
al. [9], who have also used a DD approach to study the
expression of mitochondrial-related genes in several thy-
roid tumours. Haugen et. al. [9] found in papillary carci-
nomas and in some other types of thyroid tumours
overexpression of the following mitochondrial genes that
encode for proteins of the OXPHOS system: NADH dehy-
drogenase 5, ATP synthase 6, cytochrome b and cyto-
chrome c oxidase I.
Our finding of Core I protein overexpression in some ade-
nomas shows, on the other hand, that such overexpres-
sion should not be linked to malignancy.
We observed, furthermore, that Core I protein overexpres-
sion was restricted to follicular carcinomas and to adeno-
mas with a microfollicular morphology in contrast with
its lower expression in macrofollicular adenomas. Inter-
estingly, an intermediate level of expression was found in
case 8, an adenoma displaying both macro and microfol-
licular areas (Table 3).
At variance with microfollicular adenomas and follicular
carcinomas, levels of Core I expression in papillary carci-
nomas were near-normal in all samples, regardless of hav-
ing or not Hürthle cell features.
One might assume that the overexpression of Core I pro-
tein in follicular carcinomas and microfollicular adeno-
mas could be associated with an increased proliferative
activity of such thyroid neoplasms. The results weBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/12
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obtained in the study of MIB-1 expression did not reveal,
however, any significative relationship between prolifera-
tive activity and Core I overexpression.
Taking into consideration the aforementioned results and
the association between Core I overexpression and the
microfollicular architecture of the thyroid lesions it seems
conceivable to suggest that the overexpression of Core I
protein may be linked to a putative higher metabolism of
microfollicular tumours. In mammals, different tissues
have been shown to vary substantially in mitochondrial
energy production. Such differences could result from
changes in mtDNA amount or from the differential
expression of nDNA OXPHOS genes [19]. It would be
interesting to study some hyperfunctioning thyroid
lesions, such as Grave's disease and toxic adenomas, to
find whether or not Core I protein is also overexpressed in
those lesions.
Alterations in the expression of OXPHOS enzymes have
been described in polyps of familial polyposis coli
patients [20], transformed cell lines [21], renal carcino-
mas and renal and salivary oncocytomas [22], melanoma
cells [23], prostate carcinoma [24] and breast carcinoma
[25].
We are not aware, however, of any study reporting the
overexpression of Core I protein in any of the aforemen-
tioned models. The same holds true regarding thyroid
tumours in which no alterations have been reported to
data, to the best of our knowledge, in the Core I subunit
of complex III.
The other differentially expressed fragments – N1, N2, N3,
T2 and T3 – raise a number of different issues.
The identification of genes encoding ribosomal proteins
as being differentially expressed in tumour cells when
compared with their normal counterparts has been previ-
ously reported [23,26]. In our study, the gene that
encodes for ribosomal protein L3 was found to be
expressed at higher levels in normal thyroid tissue than in
the follicular Hürthle cell carcinoma. Graack et al. [27]
described a nucleus-encoded mitochondrial ribosomal
protein in yeast, YmL9, that was found to be essential for
mitochondrial ribosomal function and to have a high
sequence and genetic similarity to human ribosomal pro-
tein L3. According to this, Graack et al. [27] postulated
that cytoplasmic ribosomal protein L3 could be a nucleus-
encoded mitochondrial ribosomal protein required for
protein synthesis by functional mitochondria. Since
Hürthle cells are characterized by a deficient protein pro-
duction and an increased number of "abnormal" mito-
chondria [28] it is tempting to hypothesize that the lower
expression of ribosomal protein L3 in Hürthle cells may
be related to an intrinsic defect of Hürthle cells. Further
studies are obviously needed to confirm our finding and,
in the affirmative case, to verify if there is any relationship
between Hürthle cell features and underexpression of
human ribosomal protein L3.
The differential expression of a rRNA 28s in the condi-
tions we have used – a DD technique using total RNA – is
considered to reflect a technical artifact and should not
therefore lead to any biopathological interpretation [10].
The Homo sapiens hypothetical gene (LOC125510) and
the  Homo sapiens KIAA1468 protein are proteins with
unknown function.
The loss of expression of thyroglobulin gene in the
tumoural tissue was expected due to the loss of differenti-
ation of tumour cells.
Conclusions
Summing up, we found overexpression of the gene encod-
ing the Core I subunit of the complex III of MRC in follic-
ular carcinomas and microfollicular adenomas of the
thyroid with or without Hürthle cells features, in contrast
with its underexpression in macrofollicular adenomas
and its near-normal levels in papillary carcinomas. No sig-
nificative correlation was found between Core I overex-
pression and the proliferative activity of the lesions. The
study of a large series of follicular lesions appears to be
necessary to clarify the pathogenetic mechanism linking
Core I overexpression to the microfollicular pattern of
growth of thyroid tumours.
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